Optical Detection of Distal Lung Enzyme Activity in Human Inflammatory Lung Disease
Open Access
- 1 January 2021
- journal article
- research article
- Published by American Association for the Advancement of Science (AAAS) in BME Frontiers
Abstract
Objective and Impact Statement. There is a need to develop platforms delineating inflammatory biology of the distal human lung. We describe a platform technology approach to detect in situ enzyme activity and observe drug inhibition in the distal human lung using a combination of matrix metalloproteinase (MMP) optical reporters, fibered confocal fluorescence microscopy (FCFM), and a bespoke delivery device. Introduction. The development of new therapeutic agents is hindered by the lack of in vivo in situ experimental methodologies that can rapidly evaluate the biological activity or drug-target engagement in patients. Methods. We optimised a novel highly quenched optical molecular reporter of enzyme activity (FIB One) and developed a translational pathway for in-human assessment. Results. We demonstrate the specificity for matrix metalloproteases (MMPs) 2, 9, and 13 and probe dequenching within physiological levels of MMPs and feasibility of imaging within whole lung models in preclinical settings. Subsequently, in a first-in-human exploratory experimental medicine study of patients with fibroproliferative lung disease, we demonstrate, through FCFM, the MMP activity in the alveolar space measured through FIB One fluorescence increase (with pharmacological inhibition). Conclusion. This translational in situ approach enables a new methodology to demonstrate active drug target effects of the distal lung and consequently may inform therapeutic drug development pathways.Funding Information
- Mauna Kea Technologies
- European Union Seventh Framework Programme (326465)
- Medtronic/Royal Academy of Engineering Research Chair (RCSRF1819\7\34)
- Cancer Research UK Clinician Scientist Fellowship (A24867)
- Wellcome Trust (203148/Z/16/Z)
- Engineering and Physical Sciences Research Council (NS/A000049/1, EP/R005257/1, EP/K03197X/1)
- Medical Research Council (MR/J014702)
This publication has 46 references indexed in Scilit:
- Pivotal Role of Matrix Metalloproteinase 13 in Extracellular Matrix Turnover in Idiopathic Pulmonary FibrosisPLOS ONE, 2013
- Infrared optical imaging of matrix metalloproteinases (MMPs) up regulation following ischemia reperfusion is ameliorated by hypothermiaBMC Neuroscience, 2012
- Effects of an oral MMP-9 and -12 inhibitor, AZD1236, on biomarkers in moderate/severe COPD: A randomised controlled trialPulmonary Pharmacology & Therapeutics, 2012
- Dual-Wavelength Imaging of Tumor Progression by Activatable and Targeting Near-Infrared Fluorescent Probes in a Bioluminescent Breast Cancer ModelPLOS ONE, 2012
- Safety and tolerability of an oral MMP-9 and -12 inhibitor, AZD1236, in patients with moderate-to-severe COPD: A randomised controlled 6-week trialPulmonary Pharmacology & Therapeutics, 2011
- Differential matrix metalloproteinase levels in adenocarcinoma and squamous cell carcinoma of the lungThe Journal of Thoracic and Cardiovascular Surgery, 2010
- Extracellular Matrix Molecules: Potential Targets in PharmacotherapyPharmacological Reviews, 2009
- Enzyme-Targeted Fluorescent Imaging Probes on a Multiple Antigenic Peptide CoreJournal of Medicinal Chemistry, 2006
- Matrix metalloproteinases (MMPs) and tissue inhibitors of MMPs in the respiratory tract: Potential implications in asthma and other lung diseasesEuropean Journal of Pharmacology, 2006
- Fluorescence Enhancement through Enzymatic Cleavage of Internally Quenched Dendritic Peptides: A Sensitive Assay for the AspN EndoproteinaseAngewandte Chemie, 2002